Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data ...
Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc (PALI), (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel ...
Corbus Pharmaceuticals reports no neuropsychiatric events in CRB-913 trial, advancing to multiple ascending dose phase. Study completion projected for Q3 2025. Corbus Pharmaceuticals Holdings Inc. has ...
Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic Validation Clinical Data Build Upon Robust Preclinical Activity Seen ...
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90% ...
BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders Consistent with Phase 1a SAD results, VYN202 demonstrated a favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results